Month: October 2022

Lawitz, Eric; Landis, Charles S; Flamm, Steven L; Bonacini, Maurizio; Ortiz-Lasanta, Grisell; Huang, Jonathan; Zhang, Jie; Kirby, Brian J; De-Oertel, Shampa; Hyland, Robert H; Osinusi, Anu O; Brainard, Diana M; Robson, Richard; Maliakkal, Benedict J; Gordon, Stuart C; Gane, Edward J published the artcile< Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.>, Computed Properties of 58-97-9, the main research area is .

BACKGROUND: There is a medical need for highly effective, safe, and well tolerated treatments for patients infected with hepatitis C virus (HCV) with severe renal impairment. We investigated the safety and efficacy of sofosbuvir with ribavirin or ledipasvir combined with sofosbuvir in a prospective study of patients with genotype 1 or 3 HCV infection and stage 4-5 chronic kidney disease (creatinine clearance by Cockcroft-Gault ≤30 mL/min) who were not on dialysis. METHODS: This phase 2b, open-label, non-randomised, multicentre study in the USA and New Zealand investigated three sequentially enrolled cohorts of patients. Patients were recruited from ten hospitals and clinical research centres and were included if they had genotype 1 or 3 HCV infection, a creatinine clearance less than or equal to 30 mL/min, and were not on dialysis. In cohorts 1 and 2, patients received sofosbuvir (200 mg in cohort 1 and 400 mg in cohort 2) plus ribavirin 200 mg once per day for 24 weeks. In cohort 3, 18 patients received ledipasvir combined with sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir) once per day for 12 weeks. The primary efficacy endpoint was the proportion of patients achieving sustained virological response 12 weeks after the end of treatment (SVR12). Safety and pharmacokinetic data were also collected. The trial is registered with ClinicalTrials.gov, number NCT01958281, and is completed. FINDINGS: This study was done between Oct 7, 2013, and Oct 29, 2017. In the sofosbuvir plus ribavirin cohorts, 32 patients were screened, of whom 20 were enrolled and assessed for efficacy and safety (ten patients in each cohort). In the ledipasvir plus sofosbuvir cohort, 33 patients were screened, of whom 18 were enrolled and assessed for treatment efficacy and safety. Four (40%, 95% CI 12-74) of ten patients in cohort 1 and six (60%, 26-88) of ten patients in cohort 2 achieved SVR12. All 18 (100%, 82-100) patients in cohort 3 achieved SVR12. Adverse events were mostly mild or moderate in severity. The most commonly reported adverse events overall were headache (eight [21%] of 38 patients), anaemia (seven [18%] of 38 patients), and fatigue (six [16%] of 38 patients). Eight patients had serious adverse events, none of which were treatment related. There were no treatment-related cardiac events or clinically significant changes in echocardiographic parameters or creatinine clearance by Cockcroft-Gault. INTERPRETATION: In this phase 2b study, ledipasvir combined with sofosbuvir for 12 weeks was safe and effective in patients with genotype 1 HCV infection and stage 4-5 chronic kidney disease who were not on dialysis. FUNDING: Gilead Sciences.

The lancet. Gastroenterology & hepatology published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Computed Properties of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Pirmoradi, Maryam; Kastner, James R. published the artcile< A kinetic model of multi-step furfural hydrogenation over a Pd-TiO2 supported activated carbon catalyst>, Related Products of 97-99-4, the main research area is furfural hydrogenation palladium titanium activated carbon catalyst kinetic model.

The multi-step, aqueous phase hydrogenation kinetics of furfural (FUR) to furfuryl alc. (FA), 2-methylfuran (2MF), tetrahydrofurfuryl alc. (THFA) and 5-hydroxy-2-pentanone (5H2P) over Pd-TiO2 on an activated carbon catalyst (derived from a monolith structure) was studied (180°C, 2.1 MPa). Titanium addition created a metal-acid functional catalyst and promoted 5H2P synthesis from furfural. A Langmuir-Hinshelwood model with two active sites (a metal site for hydrogenation steps and an acid site for ring opening step) was applied to fit the kinetic data and parameters of the reaction system were obtained using non-linear regression of exptl. data. The kinetic model showed an acceptable agreement with the exptl. data with R2 of 0.93-0.96 and concentration residuals (exptl.-model) typically ≤ 5%. Adsorption constants of 2MF and THFA were significantly lower than the adsorption constants of the other three compounds A reaction rate constant of 1.6-1.8 mol/gcat.h for furfural consumption was predicted by the model. Reaction rates of 0.2-0.35 mol/gcat.h, 0.1-0.13 mol/gcat.h and 0.8-1.0 mol/gcat.h were predicted for formation of 2-methylfuran, tetrahydrofurfuryl alc. and 5-hydroxy-2-pentanone, resp. External and internal mass transfer criterion indicate intrinsic rate parameters were estimated and indicate the model can be used to perform monolithic reactor design for aqueous phase hydrogenation of furfural.

Chemical Engineering Journal (Amsterdam, Netherlands) published new progress about Hydrogenation. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, Related Products of 97-99-4.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Lee, Jihyeon; Woo, Jinwoo; Nguyen-Huy, Chinh; Lee, Man Sig; Joo, Sang Hoon; An, Kwangjin published the artcile< Highly dispersed Pd catalysts supported on various carbons for furfural hydrogenation>, Reference of 97-99-4, the main research area is palladium nanoparticle carbon catalyst furfural hydrogenation cyclopentanone furfuryl alc.

Furfural (FAL), one of the important platform mols. derived from lignocellulosic biomass, can be converted into valuable chems. such as furfuryl alc. or cyclopentanone via hydrogenation. While carbon materials have been used as versatile catalyst supports for FAL hydrogenation, systematic studies on the structure of the catalytic performances are lacking. In this work, we prepare various types of carbon supports to investigate the impact of carbon structures for Pd-catalyzed FAL hydrogenation. Mesoporous carbons, including CMK-3, CMK-5, CMK-8, and MSU-F-C, as well as carbon nanotube and Vulcan XC are used as carbon supports. For the preparation of highly dispersed Pd-supported carbon (Pd/C) catalysts, chem. reduction by sodium borohydride is applied, in which trisodium citrate plays a critical role in anchoring small Pd clusters on the carbons. In the liquid-phase hydrogenation of FAL, CMK-5 with the largest surface area and hexagonal hollow tubular framework is proven to be the most efficient carbon support for Pd/C catalysts, with the highest conversion of FAL in both 2-propanol (100%) and water (86.4%) solvents. It is also demonstrated that the product selectivity in FAL hydrogenation over various Pd/C catalysts is changed dramatically depending on the type of solvent. The Pd/C catalysts exhibit similar fractions of product distributions containing furfuryl alc., cyclopentanol, tetrahydrofurfuryl alc., and minor products in 2-propanol. However, the production of cyclopentanone is increased when water is used as a solvent.

Catalysis Today published new progress about Carbon black Role: CAT (Catalyst Use), PRP (Properties), USES (Uses) (Vulcan XC, catalyst support). 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, Reference of 97-99-4.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Chappell, Catherine A.; Scarsi, Kimberly K.; Kirby, Brian J.; Suri, Vithika; Gaggar, Anuj; Bogen, Debra L.; Macio, Ingrid S.; Meyn, Leslie A.; Bunge, Katherine E.; Krans, Elizabeth E.; Hillier, Sharon L. published the artcile< Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study>, SDS of cas: 58-97-9, the main research area is .

Background Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiol. changes in pregnancy alter the pharmacokinetics of some medications; thus, our aim was to compare the pharmacokinetic parameters of ledipasvir 90 mg plus sofosbuvir 400 mg during pregnancy with non-pregnant women. Methods This was an open-label, phase 1 study of pregnant women with genotype 1 HCV infection and their infants. A reference group of women who had participated in pharmacokinetic studies of ledipasvir-sofosbuvir during phase 2 and 3 trials was used. Participants were enrolled at Magee-Womens Hospital (Pittsburgh, PA, USA) between 23 and 24 wk’ gestation and had a 12-wk course of oral ledipasvir-sofosbuvir (daily 90 mg ledipasvir plus 400 mg sofosbuvir). Three 12-h intensive pharmacokinetic visits were done at 25-26, 29-30, and 33-34 wk’ gestation and individual pharmacokinetics were summarised by geometric mean across the three visits. The primary outcome, analyzed in all participants without suspected dosing errors, was the ledipasvir-sofosbuvir area under the concentration-time curve of the dosing interval (AUCtau) during pregnancy compared with the reference group by geometric mean ratio. This study is registered with ClinicalTrials.gov, NCT02683005. Findings From Oct 1, 2016, to Sept 30, 2018, 29 pregnant women were screened and nine (31%) were enrolled. Eight (89%) women were included in the primary anal. Ledipasvir and sofosbuvir exposures were similar in the pregnant women vs. the non-pregnant reference group (geometric mean ratio of AUCtau ledipasvir 89·3% [90% CI 68·7-116·1]; sofosbuvir 91·1% [78·0-106·3]). Interpretation Ledipasvir-sofosbuvir was safe and effective without clin. meaningful differences in drug exposure among pregnant vs. non-pregnant women.

Lancet Microbe published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, SDS of cas: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Chen, Changzhou; Zhou, Minghao; Jiang, Jianchun published the artcile< Selective aqueous-phase hydrogenation of furfural to cyclopentanol over Ni-based catalyst under mild conditions>, Safety of (Tetrahydrofuran-2-yl)methanol, the main research area is hydrogenation furfural cyclopentanol nickel catalyst selective aqueous phase.

A series of carbon nanotube (CNT)-supported Ni-based catalysts were prepared through a simple impregnation method. The synthesized Ni-based bimetallic catalysts exhibited much smaller particle size and better dispersion than monometallic Ni/CNT catalyst. Owing to the synergistic effect of Ni with Mo, the material was especially active to hydrogenation of biomass derivatives in aqueous medium. Promotional effect was observed in NiMo/CNT catalyst during hydrogenation of furfural to fine chems., including cyclopentanone/cyclopentanol, which is of profound practical values for processing biomass degradation and may be applied in the food and biomass refining industry.

Journal of the Chinese Chemical Society (Weinheim, Germany) published new progress about Carbon nanotubes. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, Safety of (Tetrahydrofuran-2-yl)methanol.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Liu, Qianhe; Liu, Qing; Hu, Xun published the artcile< Selective conversion of furfural into value-added chemical commodity in successive fixed-bed reactors>, COA of Formula: C5H10O2, the main research area is furfural commodity successive fixed bed reactor.

Successive hydrogenation of furfural in two fixed-bed reactors connected in tandem with Cu/SiO2 and Ni/SiO2 as the catalysts was achieved under atm. pressure. Various targeting products including furfuryl alc. (yield: 98.8%), 2-methylfuran (yield: 95.1%), 2-methyltetrahydrofuran (yield: 96.2%) and tetrahydrofurfuryl alc. (yield: 78.2%) could be obtained by variation of the reactor configurations.

Catalysis Communications published new progress about Fixed-bed catalytic reactors. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, COA of Formula: C5H10O2.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Shiha, Gamal; Esmat, Gamal; Hassany, Mohamed; Soliman, Reham; Elbasiony, Mohamed; Fouad, Rabab; Elsharkawy, Aisha; Hammad, Radi; Abdel-Razek, Wael; Zakareya, Talaat; Kersey, Kathryn; Massetto, Benedetta; Osinusi, Anu; Lu, Sophia; Brainard, Diana M.; McHutchison, John G.; Waked, Imam; Doss, Wah published the artcile< Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt>, HPLC of Formula: 58-97-9, the main research area is hepatitis c virus infection ledipasvir sofosbuvir ribavirin safety Egypt; chronic hepatitis; cirrhosis; genotype.

We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 wk in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. Design In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 wk of ledipasvir/sofosbuvir±ribavirin. Among treatment-naive patients, SVR12 rates were 95% and 90% for those receiving 8 wk of ledipasvir/sofosbuvir alone and with ribavirin, resp., and 98% for those receiving 12 wk of ledipasvir/sofosbuvir both alone and with ribavirin. Among interferon-experienced patients, SVR rates were 94% for those receiving 12 wk of ledipasvir/ sofosbuvir and 100% for those receiving 12 wk of ledipasvir/sofosbuvir plus ribavirin. All patients previously treated with sofosbuvir regimens who received ledipasvir/sofosbuvir plus ribavirin achieved SVR12. The most common adverse events, headache and fatigue, were more common among patients receiving ribavirin. A mong non-cirrhotic treatment-naive patients with HCV genotype 4, 8 wk of ledipasvir/ sofosbuvir±ribavirin was highly effective. Twelve weeks of ledipasvir/sofosbuvir±ribavirin was highly effective regardless of presence of cirrhosis or prior treatment experience, including previous treatment with sofosbuvir or ledipasvir/sofosbuvir.

Gut published new progress about Anemia. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Bruna, Lauriane; Cardona-Farreny, Miquel; Colliere, Vincent; Philippot, Karine; Axet, M. Rosa published the artcile< In Situ Ruthenium Catalyst Modification for the Conversion of Furfural to 1,2-Pentanediol>, COA of Formula: C5H10O2, the main research area is ruthenium supported PVP hydrogenation catalyst value added product; biomass; furfural; nanocatalysis; pentanediol; ruthenium.

Exploiting biomass to synthesize compounds that may replace fossil-based ones is of high interest in order to reduce dependence on non-renewable resources. 1,2-Pentanediol and 1,5-pentanediol can be produced from furfural, furfuryl alc. or tetrahydrofurfuryl alc. following a metal catalyzed hydrogenation/C-O cleavage procedure. Colloidal ruthenium nanoparticles stabilized with polyvinylpyrrolidone in situ modified with different organic compounds are able to produce 1,2-pentanediol directly from furfural in a 36% of selectivity at 125°C under 20 bar of H2 pressure.

Nanomaterials published new progress about Biomass conversion catalysts. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, COA of Formula: C5H10O2.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Zhang, Qingfei; Kuang, Gaizhen; Zhou, Dongfang; Qi, Yanxin; Wang, Mingzhe; Li, Xiaoyuan; Huang, Yubin published the artcile< Photoactivated polyprodrug nanoparticles for effective light-controlled Pt(IV) and siRNA codelivery to achieve synergistic cancer therapy>, Reference of 4415-87-6, the main research area is photoactivated platinum polyprodrug nanoparticle Bcl2 siRNA synergy cancer therapy.

Endo/lysosomal escape and the subsequent controllable/precise release of drugs and genes are key challenges for efficient synergistic cancer therapy. Herein, we report a photoactivated polyprodrug nanoparticle system (PPNPsiRNA) centered on effective light-controlled codelivery of Pt(IV) prodrug and siRNA for synergistic cancer therapy. Under green-light irradiation, PPNPsiRNA can sustainedly generate oxygen-independent azidyl radicals to facilitate endo/lysosomal escape through the photochem. internalization (PCI) mechanism. Besides, concurrent Pt(II) release and siRNA unpacking could occur in a controllable manner after the decomposition of Pt(IV), main chain shattering of photoactivated polyprodrug and the PPNPsiRNA disassocn. Based on these innovative features, excellent synergistic therapeutic efficacy of chemo- and RNAi therapies of PPNPsiBcl-2 could be achieved on ovarian cancer cells under light irradiation The facile synthesized and prepared photoactivatable polyprodrug nanoparticle system provides a new strategy for effective gene/drug codelivery, where controllable endo/lysosomal escape and the subsequent drug/gene release/unpacking play vital roles, which could be adopted as a versatile codelivery nanoplatform for the treatment of various cancers.

Journal of Materials Chemistry B: Materials for Biology and Medicine published new progress about Antitumor agents. 4415-87-6 belongs to class tetrahydrofurans, and the molecular formula is C8H4O6, Reference of 4415-87-6.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Zalawadiya, Sandip K.; Lindenfeld, JoAnn; Shah, Ashish; Wigger, Mark; Danter, Matthew; Brinkley, D. Marshall; Menachem, Jonathan; Punnoose, Lynn; Balsara, Keki; Brown Sacks, Suzanne; Ooi, Henry; Perri, Roman; Awad, Joseph; Smith, Sarah; Fowler, Rachel; O’Dell, Heather; Darragh, Callie; Ruzevich-Scholl, Shelly; Schlendorf, Kelly published the artcile< Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus>, Application In Synthesis of 58-97-9, the main research area is hepatitis C virus renal impairment heart transplantation sofosbuvir antiviral.

Donor-derived hepatitis C (dd-HCV) infection may increase the risk of renal impairment (RI) among heart transplantation (HT) recipients. Sofosbuvir, an integral component of HCV direct-acting antivirals (DAAs) has also been linked to RI. To date, no study has examined the trends in renal function for HT recipients of dd-HCV infection and assessed safety and efficacy of Sofosbuvir-based DAAs. Between Sept. 2016 and June 2018, 46 HCV-naive patients and one patient with a history of HCV treated pretransplant, underwent HT from HCV-pos. donors (follow-up available through Oct. 10, 2018). Patients were treated with Ledipasvir-Sofosbuvir (genotype 1) or Sofosbuvir-Velpatasvir (genotype 3) for 12 or 24 wk; no dose adjustments were made for renal function. Data on renal function were available for 23 patients who achieved a sustained virol. response at 12 wk after the treatment (SVR12; cohort A) and 18 patients who completed 1 yr of follow-up (cohort B). All patients tolerated DAAs well with 100% completion rate to the assigned therapy and duration and 100% success at achieving SVR12. In this first and largest reported case series to date of HT recipients with dd-HCV infection, we observed that neither the dd-HCV infection nor its treatment with Sofosbuvir-based DAAs increased the risk of RI. Sofosbuvir-based DAAs appear safe, tolerable, and effective for HCV treatment even in presence of severe RI.

ASAIO Journal published new progress about Antiviral agents (direct-acting antiviral). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Application In Synthesis of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem